TMED10 INHIBITION SUPPRESSES CELL-SURFACE PD-1 EXPRESSION AND REVERSES T CELL DYSFUNCTION

ABSTRACT: PD-1 immune checkpoint blockade (ICB) is revolutionizing cancer therapy, but little is known about the mechanisms governing its expression. In a whole-genome, dual-marker FACS-based CRISPR/Cas9 screen in primary murine CD8 T cells, we found that inactivation of the EMP24/GP25L/p24 protein family, most prominently TMED10, reduced PD-1 cell-surface stability.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): T Cell, T-lymphocyte

DISEASE(S): Melanoma

SUBMITTER: Onno Bleijerveld  

LAB HEAD: Maarten Altelaar

PROVIDER: PXD026984 | Pride | 2025-05-06

REPOSITORIES: Pride